Cell Therapeutics' Pacritinib Phase III Program Takes Off
By Catherine Shaffer
Thursday, January 10, 2013
Cell Therapeutics Inc., of Seattle, began a much-anticipated Phase III trial for its JAK2 inhibitor, pacritinib, in myelofibrosis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.